Chris Grainger

I led the Vaccine Research Formulation team developing early research and preclinical vaccine formulations on a numerous disease types. Vaccine modalities are both therapeutic and prophylactic, with a range of antigentic, adjuvant and delivery platforms under investigation.

I worked within the Vaccine Research Formulation team in a small group developing early research and preclinical vaccine formulations on a numerous disease types. Vaccine modalities are both therapeutic and prophylactic, with a range of antigentic, adjuvant and delivery platforms under investigation.

Visiting lecturer at King's college London, giving annual lectures on basic vaccinology to the Pharmacy degree students

I worked as a lead formulation scientist in the development of dry powder inhaler products.

The project was concerned with the development of a system to permit deposition of pharmaceutical and environmentally relevant aerosols onto a cell culture model of the bronchial epithelium. Toxicological endpoints and permeability of the cell layer after deposition of these particles were examined to give a better prediction of systemic exposure levels in vivo..

I was invited to undertake a three month advisory position at MedImmune, CA. I was employed to build and develop a novel system of producing an inhaled vaccine of a monomodal particle size distribution for targeted delivery to the respiratory tract. Formulations using various spray drying conditions of live attenuated virus were produced to both allow virus viability and aerosolisation performance.

Worked within a small team developing a live, inhalable measles vaccine via spray drying, in collaboration with the World Health Organisation. I was ultimately responsible for the design and production of the vaccine leading to testing in an primate model in Rotterdam, Netherlands. .